PROFILE 1001: Crizotinib in Advanced Non-Small-Cell Lung Cancer With MET Exon 14 Alterations

June 3-7, 2016; Chicago, Illinois
Crizotinib shows antitumor activity, with a tolerable safety profile, in NSCLC with MET exon 14 alterations.
Format: Microsoft PowerPoint (.ppt)
File Size: 467 KB
Released: June 7, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer HealthCare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

Related Content

Downloadable powerpoint slideset with key takeways on the use of immune checkpoint inhibitors for resectable early-stage NSCLC, from Clinical Care Options (CCO)

Justin F. Gainor, MD
Program Director
Released: January 18, 2022

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in immunotherapy for early-stage NSCLC

Justin F. Gainor, MD
Program Director
Stephen V. Liu, MD
Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: January 10, 2022 Expired: January 9, 2023

Drs Enriqueta Felip and Alexander Spira discuss the emerging role of EGFR exon 20 insertion mutations in the management of advanced NSCLC, from Clinical Care Options (CCO)

Enriqueta Felip, MD Alexander Spira, MD, PhD, FACP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: December 28, 2021 Expired: December 27, 2022

From Clinical Care Options (CCO), experts review key data in genitourinary, gastrointestinal, breast, and lung cancers presented at the ESMO 2021 congress

Eva M. Ciruelos, MD, PhD Karim Fizazi, MD, PhD Eric Van Cutsem, MD, PhD person default Vamsidhar Velcheti, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: December 15, 2021 Expired: December 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings